Regnum Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGMP research report →
Companywww.regnumcorp.com
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C—C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells.
- CEO
- Robert J. Stubblefield
- IPO
- 2019
- Employees
- 1
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $2.29K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -17.22
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 101.39%
- ROIC
- -186.44%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-781,000 · -189.26%
- EPS
- $-0.03 · -193.10%
- Op Income
- $-736,000
- FCF YoY
- -5992.28%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.86
- Avg Volume
- 328.8
Get TickerSpark's AI analysis on RGMP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RGMP Coverage
We haven't published any research on RGMP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RGMP Report →